Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months Notable responses were ...
Reported $4.15 billion (YoY growth of +90%) in preliminary* full-year 2025 global product net sales, inclusive of $1.29 billion in fourth quarter sales VYVGART impact continues with approximately 19 ...
If you ever find a personal or work task daunting, you might just need to rethink how you approach it. Pomodoro apps and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback